News | Embolic Protection Devices | August 06, 2019

Cardiovascular Systems Inc. Acquires Gardia Medical Ltd.'s Wirion Embolic Protection System

Wirion System captures debris associated with peripheral vascular interventions

Cardiovascular Systems Inc. Acquires Gardia Medical Ltd.'s Wirion Embolic Protection System

August 6, 2019 — Cardiovascular Systems Inc. (CSI) has acquired the Wirion Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd.

The device, which received European CE Mark in June 2015 and U.S. Food and Drug Administration (FDA) clearance in March 2018, is a distal embolic protection filter used to capture debris that can be associated with all types of peripheral vascular intervention (PVI) procedures. Physicians typically use embolic protection devices in vessels located above the knee with long lesions, high plaque burden and poor run off.

Ehrin Armstrong, M.D., professor of medicine at the University of Colorado, said, “The use of an embolic protection device during peripheral interventions where the risk of embolization is higher provides assurance and protection from procedural complications.”

The Wirion System is easier to use and more versatile than other available embolic protection systems, according to the company, because it can be used with any .014-inch guidewire and for all types of peripheral interventions. In addition, the Wirion System is the only embolic protection device indicated for use with any atherectomy system. The WISE LE study also demonstrated a major adverse event (MAE) rate of 1.9 percent, which is lower than any other previously reported rates with other embolic filters. No clinically significant distal embolization was observed when the Wirion System was used.

WISE LE (Wirion EPS in Lower Extremities Arteries) was a multicenter study, performed in the United States and Germany and included all commercially available atherectomy systems. The primary endpoint was freedom from MAEs occurring within 30 days post-procedure and was compared with an objective performance goal derived from historical atherectomy trials. MAE was defined as a serious adverse event that resulted in death, acute myocardial infarction, thrombosis, pseudoaneurysm, dissection (grade C or greater) or clinical perforation at the filter location, clinically relevant distal embolism, unplanned amputation or clinically driven target vessel revascularization. The study also included a histopathological analysis of debris captured by the filter during the procedures.

CSI plans to commercialize the Wirion System in the U.S. following the transfer of manufacturing from Gardia Medical. CSI expects the manufacturing transfer to be completed after a 12- to 15-month transition period. Gardia will retain the rights to the Wirion System for angioplasty and stenting procedures in the carotid arteries.

For more information: www.csi360.com, www.allium-medical.com

Related Embolic Protection Device Content

VIDEO: Defining the Need for TAVR Embolic Protection

FDA Clears First TAVR Embolic Protection System

Related Content

News | Atherectomy Devices

July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately ...

Home July 20, 2020
Home
News | Atherectomy Devices

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has issued its final guidance on "Peripheral Vascular ...

Home February 13, 2020
Home
News | Atherectomy Devices

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

Home November 11, 2019
Home
News | Atherectomy Devices

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

Home November 07, 2019
Home
Technology | Atherectomy Devices

September 13, 2019 — Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Home September 13, 2019
Home
News | Atherectomy Devices

July 18, 2018 — Avinger Inc. announced in June that several physicians have successfully treated over 40 patients for ...

Home July 18, 2018
Home
Technology | Atherectomy Devices

May 24, 2018 — Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug ...

Home May 24, 2018
Home
Technology | Atherectomy Devices

January 16, 2018 — Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug ...

Home January 16, 2018
Home
News | Atherectomy Devices

January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in ...

Home January 09, 2018
Home
Technology | Atherectomy Devices

November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S. Food and ...

Home November 20, 2017
Home
Subscribe Now